Zecotek Granted Chinese Patent Rights For LFS Scintillation Material
Vancouver, BC, September 3, 2008 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) today announced that Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, has received Notification of Grant of Patent Rights from the Chinese Patent Office for its LFS scintillation material. The grant of these additional Chinese patent rights further validates and strengthens Zecotek’s worldwide patent position in its innovative LFS scintillation material.
“While our LFS scintillation material has already been granted patents in key markets, including the United States, the grant of patent rights in China provides confirmation of the uniqueness of LFS and is a welcome level of protection to our intellectual property in this important emerging market,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “Our patented LFS scintillation material is broadly recognized as a significant new material for enhancing the performance of a wide range of imaging devices, and in particular, for its effectiveness with next-generation Positron Emission Tomography (PET) medical imaging.”
Zecotek has developed and patented a new class of scintillation materials aimed directly at the next generation of PET, PET-CT and PET-MRI medical imaging scanners. When combined with Zecotek’s MAPD solid-state photo detectors, the new scintillation materials provide for scanning devices with higher resolution, which in turn enhances diagnosis, increases patient throughput and lowers overall unit costs with improved patient outcomes.
Other medical applications for LFS scintillation material are in micro-PET detectors, widely used in drug research and in gamma cameras used for breast and prostate examinations. Additional non-medical applications include gamma ray detector systems for homeland security, geological surveying, materials analysis, high energy physics and nuclear stockpile monitoring.
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industries. Founded in 2003, the company operates three distinct divisions: imaging, lasers and 3D display, with labs located in Canada, USA, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit Zecotek Photonics.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For product and technical information please contact:
Zecotek Photonics Inc.
SUSANA MENDEZ ALCALA
T: (604) 827-5232
For investor information please contact:
Caliber Capital Partners
T: (778) 327-6678
E: [email protected]
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.